Gut Liver.  2016 Sep;10(5):706-713. 10.5009/gnl15510.

Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

• Gong EJ
• Ahn JY
• Jung HY
• Park H
• Ko YB
• Na HK
• Jung KW
• Kim DH
• Lee JH
• Choi KD
• Song HJ
• Lee GH
• Kim JH

• KMID: 2412066
• DOI: http://doi.org/10.5009/gnl15510

Abstract

BACKGROUND/AIMS
We investigated the effectiveness of Helicobacter pylori eradication therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma regardless of the H. pylori infection status or disease stage.
METHODS
From November 1995 to September 2014, 345 subjects who were diagnosed with gastric MALT lymphoma and had received eradication therapy as their first-line treatment were eligible for inclusion in this study. A retrospective review was performed using the medical records.
RESULTS
Of the 345 patients, H. pylori infection was detected in 317 patients (91.9%). The complete remission (CR) rate after eradication therapy was 82.3%, which was higher in H. pylori-positive patients than in H. pylori-negative patients (84.5% vs 57.1%, p=0.001). CR rates after eradication did not present significant differences between stages, and the CR rate was 83.3% for stage IE1 and 74.4% for stage IE2 or above (p=0.167). The overall CR rate was 87.2% after additional treatment, and neither H. pylori infection status nor stage showed differences according to the treatment response.
CONCLUSIONS
Eradication therapy led to CR in 57.1% of H. pylori-negative patients and in 74.4% of patients with stage IE2 or above. Eradication therapy is worthwhile as an initial treatment for gastric MALT lymphoma regardless of the H. pylori infection status and stage.

Keyword

Helicobacter pylori; Mucosa-associated lymphoid tissue lymphoma; Remission

MeSH Terms

Anti-Bacterial Agents/*therapeutic use
Female
Gastric Mucosa/drug effects/microbiology
Helicobacter Infections/complications/*drug therapy/microbiology
*Helicobacter pylori
Humans
Lymphoma, B-Cell, Marginal Zone/*drug therapy/microbiology
Male
Middle Aged
Remission Induction
Retrospective Studies
Stomach Neoplasms/*drug therapy/microbiology
Anti-Bacterial Agents